VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
TXMDTherapeuticsMD, Inc.
$2.11$24M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksTXMDCash Flow

TherapeuticsMD, Inc. (TXMD) Cash Flow Statement

30Y historyFree accessUpdated daily

Free cash flow remains precarious and inconsistent, with margins swinging between -33.8% and 133.4%, reflecting a business model that struggles to generate reliable cash to cover its corporate administrative footprint.

TXMD Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Cash from Operations2.67M2.42M732K-48.14M-4.08M-147.81M-159.47M-165.7M-106.81M-76.16M-69.14M-79.04M-45.52M-20.77M-12.74M-4.97M836.83K-417.34K-133K344.1K329.84K412.34K207.73K140K100.08K161.95K133.97K48.53K44.6K77.53K58.78K
Operating CF Margin %-80.21%41.57%-3697.47%-5.83%-5744.69%-245.82%-333.75%-663.45%-453.91%-357.21%-392.42%-302.94%-236.66%-333.61%-237.84%1735.55%-3948.7%--32.81%44.12%33.4%31.99%34.92%48.7%36.4%22.66%22.99%40.15%24.09%
Operating CF Growth %3604.76%231.15%101.52%-1080.51%97.24%7.31%3.76%-55.13%-40.25%-10.14%12.53%-73.64%-119.19%-63.05%-156.46%-693.5%300.52%-213.78%-138.65%4.32%-20.01%98.5%48.37%39.9%-38.2%20.88%176.05%8.82%-42.47%31.88%-7.35%
Net Income179K-653K-2.31M-7.7M1.07M-79.31M-183.52M-176.15M-132.62M-76.93M-89.88M-85.08M-54.22M-28.42M-35.12M-12.91M-695.38K-1.65M-395.55K170.54K373.01K289.89K142.12K94.11K98.91K61.53K131.67K12.43K-15.58K-12.74K73.79K
Depreciation & Amortization1.42M1.19M509K922K1.19M736K4.07M1.39M293.89K213.12K132.45K62.4K52.47K58.15K56.26K54.84K61.38K76.2K0054.37K55.19K42K00000000
Stock-Based Compensation000011.57M010.68M10.68M8.66M6.89M17.41M7.19M4.24M3.21M1.87M7.79M000000000000000
Deferred Taxes000000010.44M216.02K000-5.44K-15.49K17.06M30.22K000000000000000
Other Non-Cash Items-37K221K875K-23.92M-13.83M-73.83M12.65M1.92M269.86K4.21K2.52M22.16K990.98K3.19M1.99M-168.98K831.53K685.57K250K182.46K-112K41.92K47.72K61.57K8.97K52.29K49.23K47.67K45.23K81.73K-1.93K
Working Capital Changes1.2M1.66M1.66M-17.45M-4.09M4.59M-3.34M-14M16.36M-6.34M664.75K-1.24M3.42M1.21M1.41M240.18K639.29K475.43K12.55K-8.9K14.46K25.35K-24.1K-15.68K-7.81K48.12K-46.93K-11.57K14.95K8.53K-13.08K
Change in Receivables00000-4.33M-8.22M-13.64M-6.95M167.69K-3.98M-917.66K-458.03K-1.07M-620.47K-16.41K3.52K-10.57K86.73K0000-31.58K27842.52K-45.33K-11.24K-5.42K6.37K0
Change in Inventory00000-711K-3.34M-8.59M-1.78M-409.04K-386.17K491.96K-138.5K571.59K-1.03M30K1.98M271.76K-89.36K0000-326.47K-425.48K-386.94K-271.29K-95.4K3.59K-204.39K0
Change in Payables-139K119K231K-2.13M-1.21M-1.06M1.89M-3.56M18.65M-3.26M4.23M-3.2M4.21M472.85K1.33M188.88K19.05K229.04K-3.51K00005.9K-2.09K6.73K-3.61K4.38K14.91K1.21K0
Cash from Investing0000223.48M-2.22M-1.6M-23.91M-21.5M-827.11K-1.26M-584.36K-606.76K-583.56K-272.51K-37.64K-285.5K-841.3K022.76K54.25K-68.37K-104.55K-311.99K-152.47K-14.51K08.46K-196.37K-94.96K141.29K
Capital Expenditures0000-355K-2.22M-207K-23.89M-21.32M-827.11K-1.24M-584.36K-617.44K-479.82K-272.51K-37.64K0-841.3K00-57.75K-92.23K-311.05K-247.71K-62.66K-21.7K00-211.37K-95.4K0
CapEx % of Revenue0%--3697.47%0.51%86.4%0.32%48.12%132.44%4.93%6.41%2.9%4.11%5.47%7.14%1.8%-7960.03%--5.74%9.87%50.01%56.61%21.86%6.53%--108.97%49.41%-
Acquisitions0000000000000000000000000000000
Investments-------------------------------
Other Investing0000223.83M0-1.39M-20.42K-175.41K-765.29K-14.04K-419.1K10.69K-103.74K-206.1K-8.87K-285.5K0022.76K112K23.86K77.56K-43.36K8.16K-15K08.46K00133.28K
Cash from Financing0003.15M-235.21M134.67M80.72M188.83M162.79M72.58M137.23M92.97M43.3M73.99M14.44M4.71M-550K1.3M-221.21K-943.95K-300.62K300.62K010K30K-2000-13.57K-818-250-53.44K
Debt Issued (Net)0000-219.43M-50M50M118.34M75M0000-4.69M6.35M2.98M0600.7K000450K00000-23.37K23.37K0-50K
Equity Issued (Net)0003.15M-14.51M184.67M31.7M77.03M89.91M68.57M134.86M91.37M42.77M78.65M7.9M1.71M3.17M700K-46.57K000000-2000-400-24.19K-250-3.44K
Dividends Paid000000000000000000-174.64K000000000000
Share Repurchases0000-38.66M0000000000000-46.57K000000-2000-200-24.19K-2500
Other Financing0000-1.27M0-978K-6.54M-2.12M4.01M2.36M1.6M526.75K30.91K191.4K17.25K-3.72M00-943.95K-300.62K-149.38K010K30K0010.2K000
Net Change in Cash2.67M2.42M732K-44.99M-15.8M-15.58M-80.34M-783.36K34.48M-4.4M66.83M13.34M-2.83M52.64M1.43M-296.52K1.33K42.07K-354.21K-577.1K83.47K644.59K103.18K-161.98K-22.4K147.24K133.92K43.42K-152.59K-17.68K146.63K
Free Cash Flow2.67M2.42M732K0-4.43M-147.84M-161.07M-189.59M-128.13M-76.98M-70.38M-79.63M-46.14M-21.25M-13.01M-5M836.83K-1.26M-133K344.1K272.09K320.11K-103.33K-107.7K37.41K140.24K133.97K48.53K-166.77K-17.88K58.78K
FCF Margin %79.75%80.21%41.57%--6.34%-5746.02%-248.29%-381.88%-795.89%-458.84%-363.62%-395.32%-307.05%-242.12%-340.75%-239.65%1735.55%-11908.73%--27.07%34.25%-16.61%-24.61%13.05%42.17%36.4%22.66%-85.98%-9.26%24.09%
FCF Growth %90.05%231.15%-100%97%8.21%15.04%-47.96%-66.45%-9.38%11.61%-72.59%-117.14%-63.32%-159.98%-698%166.49%-846.32%-138.65%26.46%-15%409.8%4.06%-387.88%-73.32%4.68%176.05%129.1%-832.83%-130.41%11.14%
FCF per Share0.230.210.06--0.49-18.57-29.22-38.48-28.47-18.73-17.95-22.99-15.41-8.33-7.10-4.000.11-0.87-0.221.110.820.97-0.31-0.320.110.450.430.15-0.54-0.060.19
FCF Conversion (FCF/Net Income)14.94x-4.26x-0.34x4.68x-0.04x0.86x0.87x0.94x0.81x0.99x0.77x0.93x0.84x0.73x0.36x0.38x-1.20x0.25x0.34x2.02x0.88x1.42x1.46x1.49x1.01x2.63x1.02x3.90x-2.86x-6.09x0.80x
Interest Paid00000025.85M000000000000000000000000
Taxes Paid0000000000000000000000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowMixed
Top Statement Risk

Administrative overhead exceeding revenue

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Quality Masked by Accruals

According to recent financial disclosures, the relationship between net income and operating cash flow is highly erratic, with OCF/NI ratios swinging wildly from -1.05 to 9.85, suggesting that reported earnings are currently poor proxies for the actual cash-generating capacity of the underlying royalty-based business model.

The frequent divergence between net income and operating cash flow indicates that non-cash items and working capital fluctuations are the primary drivers of reported figures rather than core operational performance. Investors should monitor this volatility, as it suggests that the company's cash position is highly sensitive to timing differences in royalty receipts rather than consistent, predictable earnings growth.

Free Cash Flow Remains Precarious

As reported in quarterly filings, the free cash flow trajectory is inconsistent, with margins fluctuating between -33.8% and 133.4% over the last ten periods, reflecting a business that lacks the scale to generate reliable, self-sustaining cash flows to cover its ongoing corporate administrative requirements.

The inability to maintain a positive and stable FCF margin highlights the structural challenge of transitioning to a royalty-only entity while maintaining a legacy cost base. This inconsistency suggests that the company remains in a defensive posture where cash flow is more a function of sporadic milestone payments than a steady, compounding revenue stream.

Working Capital Volatility Drives Liquidity

Based on the company's reported cash flow statements, working capital changes have been a significant, albeit volatile, source of cash, with quarterly adjustments reaching as high as $975K, which appears to be masking the underlying weakness in core operational cash generation for the firm.

The reliance on working capital shifts to bolster operating cash flow suggests that the company is managing its payables and receivables aggressively to preserve its limited cash runway. This pattern warrants further investigation, as it may indicate that the company is pulling forward cash inflows or delaying outflows to avoid liquidity shortfalls.

Hidden Costs of Corporate Shell

As indicated by the provided data, the cash flow statement obscures the true cost of maintaining the corporate entity, as the absence of significant capital expenditures is offset by persistent administrative burn that prevents the accumulation of meaningful cash reserves for future growth or strategic investment.

The lack of investment in new assets suggests that the company is effectively in a liquidation-like state, where the primary focus is on preserving existing cash rather than deploying it for expansion. This structure implies that the company may be vulnerable to any disruption in royalty payments, as there is little operational flexibility to absorb unexpected costs.

TXMD — Frequently Asked Questions

Quick answers to the most common questions about buying TXMD stock.

How much cash does TherapeuticsMD, Inc. (TXMD) generate from operations?

TherapeuticsMD, Inc. (TXMD) generated $2.4M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is TherapeuticsMD, Inc.'s free cash flow?

TherapeuticsMD, Inc. (TXMD) generated $2.4M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is TherapeuticsMD, Inc.'s capital expenditure (CapEx)?

TherapeuticsMD, Inc. (TXMD) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.